The Bird Flu / Swine Flu / MRSA / SuperBug Stock Page

[Rawnoc]

UW-Madison official says swine flu wave likely

http://www.chicagotribune.com/news/chi-ap-wi-swineflu-uw,0,1618941.story

[TechKim]

Danger at home: Rare form of TB comes to U.S.
First U.S. case of extremely drug-resistant strain of tuberculosis diagnosed

http://www.msnbc.msn.com/id/34516639/ns/health-infectious_diseases/


Oswaldo Juarez looks out of the window from his room at the A.G. Holley State Hospital on June 4 in Lantana, Fla. Shortly after coming to the United States to study English at age 19, Juarez was diagnosed with extremely drug-resistant tuberculosis, the first case ever seen in this country. He was treated at a sanitarium for nearly two years before being discharged.


By Martha Mendoza and Margie Mason

updated 11:50 a.m. ET, Sun., Dec . 27, 2009
Editor's note: Once curable diseases such as tuberculosis and malaria are rapidly mutating into aggressive strains that resist drugs. The reason: The misuse of the very drugs that were supposed to save us has built up drug resistance worldwide. First of a five-part series.

LANTANA, Fla. - It started with a cough, an autumn hack that refused to go away.

Then came the fevers. They bathed and chilled the skinny frame of Oswaldo Juarez, a 19-year-old Peruvian visiting the United States to study English. His lungs clattered, his chest tightened and he ached with every gasp. During a wheezing fit at 4 a.m., Juarez felt a warm knot rise from his throat. He ran to the bathroom sink and spewed a mouthful of blood.

I'm dying, he told himself, "because when you cough blood, it's something really bad."

It was really bad, and not just for him.

Doctors say Juarez's incessant hack was a sign of what they have both dreaded and expected for years — this country's first case of a contagious, aggressive, especially drug-resistant form of tuberculosis. The Associated Press learned of his case, which until now has not been made public, as part of a six-month look at the soaring global challenge of drug resistance.

Juarez's strain — so-called extremely drug-resistant (XXDR) TB — has never before been seen in the U.S., according to Dr. David Ashkin, one of the nation's leading experts on tuberculosis. XXDR tuberculosis is so rare that only a handful of other people in the world are thought to have had it.

"He is really the future," Ashkin said. "This is the new class that people are not really talking too much about. These are the ones we really fear because I'm not sure how we treat them."

Forty years ago, the world thought it had conquered TB and any number of other diseases through the new wonder drugs: antibiotics. U.S. Surgeon General William H. Stewart announced it was "time to close the book on infectious diseases and declare the war against pestilence won."

Today, all the leading killer infectious diseases on the planet — TB, malaria and HIV among them — are mutating at an alarming rate, hitchhiking their way in and out of countries. The reason: overuse and misuse of the very drugs that were supposed to save us.

Just as the drugs were a manmade solution to dangerous illness, the problem with them is also manmade. It is fueled worldwide by everything from counterfeit drugmakers to the unintended consequences of giving drugs to the poor without properly monitoring their treatment. Here's what the AP found:

In Cambodia, scientists have confirmed the emergence of a new drug-resistant form of malaria, threatening the only treatment left to fight a disease that already kills 1 million people a year.
In Africa, new and harder to treat strains of HIV are being detected in about 5 percent of new patients. HIV drug resistance rates have shot up to as high as 30 percent worldwide.
In the U.S., drug-resistant infections killed more than 65,000 people last year — more than prostate and breast cancer combined. More than 19,000 people died from a staph infection alone that has been eliminated in Norway, where antibiotics are stringently limited.
"Drug resistance is starting to be a very big problem. In the past, people stopped worrying about TB and it came roaring back. We need to make sure that doesn't happen again," said Dr. Thomas Frieden, director of the U.S. Centers for Disease Control and Prevention, who was himself infected with tuberculosis while caring for drug-resistant patients at a New York clinic in the early '90s. "We are all connected by the air we breathe, and that is why this must be everyone's problem."

This April, the World Health Organization sounded alarms by holding its first drug-resistant TB conference in Beijing. The message was clear — the disease has already spread to all continents and is increasing rapidly. Even worse, WHO estimates only 1 percent of resistant patients received appropriate treatment last year.

"We have seen a huge upburst in resistance," said CDC epidemiologist Dr. Laurie Hicks.

A ‘time bomb’
Juarez' strain of TB puzzled doctors. He had never had TB before. Where did he pick it up? Had he passed it on? And could they stop it before it killed him?

At first, mainstream doctors tried to treat him. But the disease had already gnawed a golf-ball-sized hole into his right lung.


This photo taken July 30 shows X-rays from a tuberculosis patient at A. G. Holley State Hospital, a quarantine hospital in Lantana, Fla., that is now managing new and virulent forms of the disease.

TB germs can float in the air for hours, especially in tight places with little sunlight or fresh air. So every time Juarez coughed, sneezed, laughed or talked, he could spread the deadly germs to others.

"You feel like you're killing somebody, like you could kill a lot of people. That was the worst part," he said.

Tuberculosis is the top single infectious killer of adults worldwide, and it lies dormant in one in three people, according to WHO. Of those, 10 percent will develop active TB, and about 2 million people a year will die from it.

Simple TB is simple to treat — as cheap as a $10 course of medication for six to nine months. But if treatment is stopped short, the bacteria fight back and mutate into a tougher strain. It can cost $100,000 a year or more to cure drug-resistant TB, which is described as multi-drug-resistant (MDR), extensively drug-resistant (XDR) and XXDR.

There are now about 500,000 cases of MDR tuberculosis a year worldwide. XDR tuberculosis killed 52 of the first 53 people diagnosed with it in South Africa three years ago.

Drug-resistant TB is a "time bomb," said Dr. Masae Kawamura, who heads the Francis J. Curry National Tuberculosis Center in San Francisco, "a manmade problem that is costly, deadly, debilitating, and the biggest threat to our current TB control strategies."
Juarez underwent three months of futile treatment in a Fort Lauderdale hospital. Then in December 2007 he was sent to A.G. Holley State Hospital, a 60-year-old massive building of brown concrete surrounded by a chain-link fence, just south of West Palm Beach.

"They told me my treatment was going to be two years, and I have only one chance at life," Juarez said. "They told me if I went to Peru, I'm probably going to live one month and then I'm going to die."

Holley is the nation's last-standing TB sanitarium, a quarantine hospital that is now managing new and virulent forms of the disease.

Tuberculosis has been detected in the spine of a 4,400-year-old Egyptian mummy. In the 1600s, it was known as the great white plague because it turned patients pale. In later centuries, as it ate through bodies, they called it "consumption." By 1850, an estimated 25 percent of Europeans and Americans were dying of tuberculosis, often in isolated sanatoriums like Holley where they were sent for rest and nutrition.

Then in 1944 a critically ill TB patient was given a new miracle antibiotic and immediately recovered. New drugs quickly followed. They worked so well that by the 1970s in the U.S., it was assumed the disease was a problem of the past.

Once public health officials decided TB was gone, the disease was increasingly missed or misdiagnosed. And without public funding, it made a comeback among the poor. Then immigration and travel flourished, breaking down invisible walls that had contained TB.

Drug resistance emerged worldwide. Doctors treated TB with the wrong drug combinations. Clinics ran out of drug stocks. And patients cut their treatment short when they felt better, or even shared pills with other family members.

There are two ways to get drug-resistant TB. Most cases develop from taking medication inappropriately. But it can also be transmitted like simple TB, a cough or a sneeze.

In the 1980s, HIV and AIDS brought an even bigger resurgence of TB cases. TB remains the biggest killer of HIV patients today.

For decades, drug makers failed to develop new medicines for TB because the profits weren't there. With the emergence of resistant TB, several private drug companies have started developing new treatments, but getting an entire regimen on the market could take 24 years. In the meantime, WHO estimates each victim will infect an average of 10 to 15 others annually before they die.

A.G. Holley was back in business.

No textbook answers
Holley's corridors are long and dark, with fluorescent tubes throwing harsh white light on drab walls. One room is filled with hulking machines once used to collapse lungs, sometimes by inserting ping pong balls. Antique cabinets hold metal tools for spreading and removing ribs — all from a time when TB was rampant and the hospital's 500 beds were filled.

Only 50 beds are funded today, but those are mostly full. More than half the patients are court-ordered into treatment after refusing to take their meds on the outside.

Juarez came voluntarily. In the beginning, he was isolated and forced to wear a mask when he left his room. He could touch his Peruvian family only in pictures taped to the wall. He missed his dad, his siblings, his dog, his parrot, and especially his mother.

"I was very depressed," he said. "I had all this stuff in my mind."

He spent countless hours alone inside the sterile corner room reserved for patients on extended stays — dubbed "the penthouse" because it is bigger and lined by a wall of windows.

His moods ran hot and cold. He punched holes in the walls out of frustration, played loud reggaeton music with a thumping beat and got into fights with other patients. He covered his door's small window with a drawing of an evil clown to keep nurses from peering inside. He made friends with new patients, but was forced to stay long after many of them came, got cured, and left.

Early on, Juarez's treatment was similar to chemotherapy. Drugs were pumped into his bloodstream intravenously three times a day, and he choked down another 30 pills, including some that turned his skin a dark shade of brown. He swallowed them with spoonfuls of applesauce, yogurt, sherbet and chocolate pudding, but once they hit his stomach, waves of nausea sometimes sent him heaving. He would then have to force them all down again.

"When he first came in we really had to throw everything and the kitchen sink at him," said Ashkin, the hospital's medical director, who experimented on Juarez with high doses of drugs, some not typically used for TB. "It was definitely cutting edge and definitely somewhat risky because it's not like I can go to the textbooks or ... journal articles to find out how to do this."

After 17 years of handling complex cases — including TB in the brain and spine — Ashkin had never seen a case so resistant. He believed he would have to remove part of Juarez's lung.

Ashkin dialed Peru to talk to the young man's father.

It's a rare disease, said Ashkin, hard to define. Your son is one of two people in the world known to have had this strain, he said.

"What happened to the other person?" his father asked.

"He died."

A medical nightmare
Juarez's adventure in the U.S. had turned into a medical nightmare.

About 60 million people visit the U.S. every year, and most are not screened for TB before arrival. Only refugees and those coming as immigrants are checked. The top category of multidrug-resistant patients in the U.S. — 82 percent of the cases identified in 2007 — was foreign-born patients, according to the CDC.

The results are startling among those tested, said Dr. Angel Contreras, who screens Dominicans seeking to enter the U.S. on immigrant visas. The high rate of MDR-TB in the Dominican Republic coupled with high HIV rates in neighboring Haiti are a health crisis in the making, he said.

"They're perfect ingredients for a disaster," he said.

Juarez's homeland, Peru, is also a hotspot for multidrug-resistant TB. DNA fingerprinting linked his disease to similar strains found there and in China, but none with the same level of resistance.

"So the question is: Is this a strain that's evolving? That's mutating? That's becoming more and more resistant?" asked Ashkin. "I think the answer is yes."

Doctors grappling with these new strains inadvertently give the wrong medicines, and so the TB mutates to become more aggressive and resistant.

Poor countries also do not have the resources to determine whether a patient's TB is drug-resistant. That requires sputum culturing and drug-susceptibility testing — timely, expensive processes that must be performed in capable labs. WHO is working to make these methods more available in high-risk countries as well as negotiating cheaper prices for second-line drugs.

"There's a lot of MDR and XDR-TB that hasn't been diagnosed in places like South Africa and Peru, Russia, Estonia, Latvia," said Dr. Megan Murray, a tuberculosis expert at Harvard. "We think it's a big public health threat."

Experts argue if wealthy countries do not help the worst-hit places develop comprehensive TB programs, it puts everyone at risk.

"You're really looking at a global issue,'" said Dr. Lee Reichman, a TB expert at the New Jersey Medical School Global Tuberculosis Institute. "It's not a foreign problem, you can't keep these TB patients out. It's time people realize that."

TB can return
Juarez spent a year and a half living alone in a room plastered with bikini-clad blondes, baseball caps and a poster of Mt. Everest for inspiration. There were days when he simply shut down and refused his meds until his family convinced him to keep fighting.

"I was thinking that maybe if I need to die, then that's what I need to do," he said, perched on his bed in baggy jeans. "I felt like: 'I'm never going to get better. I'm never going to get out of here.'"

When put side by side, his CAT scans from before and after treatment are hard to believe. The dark hole is gone, and only a small white scar tattoos his lung.

"They told me the TB is gone, but I know that TB, it doesn't have a cure. It only has a treatment like HIV," he said, his English now fluent and his body weight up 32 pounds from when he first arrived. "The TB can come back. I saw people who came back to the hospital twice and some of them died. So, it's very scary."

His treatment cost Florida taxpayers an estimated $500,000, a price tag medical director Ashkin says seems like an astronomical amount to spend on someone who's not an American citizen. But he questions how the world can afford not to treat Juarez and others sick with similar lethal strains.

"This is an airborne spread disease ... so when we treat that individual, we're actually treating and protecting all of us," he said. "This is true homeland security."

In July, at age 21 — 19 months after checking in — Juarez swallowed his last pills, packed a few small suitcases and wheeled them down the hospital's long corridor.

The last time doctors saw him, he was walking out of the sanitarium into south Florida's soupy heat.

© 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

[BUDDIEE18]

EUROPEAN PARLIAMENT TO INVESTIGATE WHO IN JANUARY 2010

[from an email i rec'd -- and comments are from the sender -- a Canadian ]

Some of the senators who voted for bill C6 unamended are criminal and wish to help their investments in pharmaceuticals in league with some of the criminal MP's who voted to push it through unamended....They voted to have your house broken into without a search warrant. They voted to criminally effect a theft of your freedom and privacy and can be criminally charged for a breach of trust....122 of the criminal code

Please forward this email on to your lists as the health officers are also complicit in aiding and abetting criminal activity.


Apparently not everyone in positions of authority is rolling over in compliant obedience to the World Health Organization’s Code 6 Pandemic Declaration. In Europe there are still a few people who recognize a fraudulent Scam when they see one, and they are prepared to demand an investigation to unearth the all too obvious TRUTH.
Note that this demand is coming, not from irrational, misinformed fanatics, but from the very top echelons of governance in the EU.
-----------------------------------------------


Some of the senators who voted for bill C6 unamended are criminal and wish to help their investments in pharmaceuticals in league with some of the criminal MP's who voted to push it through unamended....They voted to have your house broken into without a search warrant. They voted to criminally effect a theft of your freedom and privacy and can be criminally charged for a breach of trust....122 of the criminal code

Please forward this email on to your lists as the health officers are also complicit in aiding and abetting criminal activity.


Apparently not everyone in positions of authority is rolling over in compliant obedience to the World Health Organization’s Code 6 Pandemic Declaration. In Europe there are still a few people who recognize a fraudulent Scam when they see one, and they are prepared to demand an investigation to unearth the all too obvious TRUTH.
Note that this demand is coming, not from irrational, misinformed fanatics, but from the very top echelons of governance in the EU.
-----------------------------------------------
http://www.theflucase.com/index.php?option=com_content&view=article&id=2350%3Aeuropean-parliament-to-investigate-who-in-january-2010&catid=41%3Ahighlighted-news&Itemid=105&lang=en
EUROPEAN PARLIAMENT TO INVESTIGATE WHO IN JANUARY 2010
The Council of Europe member states are to launch an inquiry in January 2010 on the influence of the pharmaceutical companies on the global swine flu campaign, focussing especially on extent of the pharma‘s industry’s influence on WHO, according to reports in the German media.

www.zeit.de/politik/2009-12/schweinegrippe-europa

www.tagesspiegel.de/politik/international/Schweinegrippe-Europarat;art123,2976433

Wolfgang Wodarg , former SPD member of parliament, and chairman of the European parliament’s health committee, initiated the inquiry. The motion was passed unanimously by his colleagues in the European parliament‘s health committee.

Wodarg has criticised the measures taken against the swine flu as „one of the biggest medical scandals of the century.“

He said the influence of the the pharamaceutical industry on scientists and government officials has resulted in „millions of healthy people being exposed unnecessarily to the risks of an inadequately tested vaccine.“

That even though, the swine flu virus is „much less harmful“ than last year’s seasonal flu causing „not even a tenth of the usual deaths associated with flu.“

Wodarg has also criticised the way pharemceutical companies have made gigantic profits at the expense of tax payers.

He accused vaccine manufacturers of being willing even to inflict bodily harm“ in their pursuit of profits, noting that the adjuvants in the swine flu jab have hardly been tested.

In addition, the vaccine‘s side effects including dangerous paralysis have not been adequately recorded.

Wodarg has said that the role of the WHO and its pandemic emergency declaration in June needs to be the special focus of a European parliamentary inquiry. For the first time the criteria for a pandemic was made not the actual risk of a diseases but the number of cases of the disease.

By classifying the swine flu as pandemic, nations were compelled to implement pandemic plans and also the purchase swine flu vaccines.

Because WHO is not subject to any parliamentary control, Wodarg argued it is necessary for governments to insist on accountability.

What is a pandemic should not be allowed to be defined by an organisation that is clearly under the influence of the pharmaceutical companies that profit from the sales of vaccines accompanying such a pandemic. Many of the decision-makers in WHO have worked for the pharma industry and go back to work in the pharma industry.

The inquiry is also to look at the role of the Paul-Ehrlich and the Robert-KochInstitute in Germany.





--
If you bow to defacto governments it is not only your knees that will be sore!

http://www.allcreatorsgifts.org

[cfoofme]

Blood molecule could be key to fatal H1N1 cases/interleukin 17

By SHARON LEM, QMI AGENCY
Last Updated: 24th December 2009, 3:31am

TORONTO -- Scientists have found the first clue as to why some people are hospitalized and die when infected with the H1N1 virus, while others only have a mild form of the pandemic flu.

A new study by Canadian and Spanish researchers shows the difference was related to the amount of interleukin 17 in a patient's blood.

There were high levels in patients with severe cases of H1N1, while those with mild symptoms had low levels.

Interleukin 17 helps regulate white blood cells, which fight infection and disease.

The finding could lead to development of a drug to prevent the severe form of H1N1.

"In rare cases, the virus causes lung infections requiring patients to be treated in hospital," said Dr. David Kelvin, of the Toronto General Hospital Research Institute.

"By targeting or blocking interleukin 17 in the future, we could potentially reduce the amount of inflammation in the lungs and speed up recovery," he said, adding such treatment would be years away.

A test to determine who has high levels of the molecule is possible in the near future, Kelvin said.

"A diagnostic test could let us know early who is at risk for the severe form of this illness quickly," he said.

High levels of this molecule would indicate a failure of the immune system to eliminate the virus, similar to what happened during the 1918 Spanish flu when huge numbers of deaths occurred due to an already deadly influenza A virus strain of subtype H1N1.

Dr. Jesus Bermejo-Martin, an immunologist at the National Influenza Centre in Spain, said interleukin 17 was previously found by other scientists to be elevated in people with autoimmune diseases.

"When we think in a pandemic, everything relies on the virus's treatment, antivirals, vaccines, hygienic measure, but much less attention is paid to the role of the host individual's response to the virus," Bermejo-Martin said.

"We believe the treatment strategies targeting the host's responses to the virus can represent a good alternative to improve severe disease caused by influenza viruses."

The study is published in the journal Critical Care.

[e-mail]

http://www.edmontonsun.com/news/canada/2009/12/24/12259441-sun.html

[b9molecule]

AMAR .19 -- for anyone interested, a previously released interview with lead scientist on Perth, Australia clinical study wrapping up currently. Radio interview gives easy to follow synopsis on the history and current use of low dose interferon alpha for prevention of cold and flu:

http://www.amarbio.com/radio-interview.html
(ten minutes)

[b9molecule]

AMAR .19 insider exercised options for common yesterday
http://www.sec.gov/Archives/edgar/data/1014763/000137703609000002/xslF345X03/primary_doc.xml

they are loading up!
many Form 4's in the last few weeks.

[webpence]

WHO ‘Mr Flu’ under investigation
for gross conflict of interest
author of Full Spectrum Dominance: Totalitarian Democracy in the New World Order
by F. William Engdahl
December 8, 2009

The man with the nickname “Dr Flu”, Professor Albert Osterhaus, of the Erasmus University in Rotterdam Holland has been named by Dutch media researchers as the person at the center of the worldwide Swine Flu H1N1 Influenza A 2009 pandemic hysteria. Not only is Osterhaus the connecting person in an international network that has been described as the Pharma Mafia, he is THE key advisor to WHO on influenza and is intimately positioned to personally profit from the billions of euros in vaccines allegedly aimed at H1N1.

Earlier this year the Second Chamber of the Netherland Parliament undertook an investigation into alleged conflicts of interest and financial improprieties of the well-known Dr. Osterhaus. Outside Holland and a mention at the time in the Dutch media, the only note of the sensational investigation into Osterhaus’ business affairs came in a tiny note in the respected British magazine, Science.

Osterhaus's credentials and expertise in his field were not in question. What is according to a short report published by the journal Science, are his links to corporate interests that stand to potentially profit from the swine flu pandemic. Science carried the following brief note in its October 16 2009 issue about Osterhaus:

" For the past 6 months, one could barely switch on the television in the Netherlands without seeing the face of famed virus hunter Albert Osterhaus talking about the swine flu pandemic. Or so it has seemed. Osterhaus, who runs an internationally renowned virus lab at Erasmus Medical Center, has been Mr. Flu. But last week, his reputation took a nosedive after it was alleged that he has been stoking pandemic fears to promote his own business interests in vaccine development. As Science went to press, the Dutch House of Representatives had even slated an emergency debate about the matter."1

Full article here
http://www.financialsense.com/editorials/engdahl/2009/1208.html

[sludgehound]

Ancient HIV stowaway may hold clue to transmission
Sun, Dec 6 2009
WASHINGTON (Reuters) - An HIV genetic stowaway that may have come from a related cat virus could help the AIDS virus transmit and replicate in people, U.S. researchers reported on Sunday.

Their finding, which has implications for designing new drugs or a vaccine against the fatal and incurable virus, may also shed light on how other viruses, such as swine flu, spread from animals to people, experts said.

And it also may help explain how an ancient virus came to cause the devastating 25-year-long pandemic of AIDS.

Dr. Robert Bambara of the University of Rochester Medical Center in New York and colleagues found the previously unnoticed stretch of genetic material in the RNA sequence of the virus. HIV is a so-called retrovirus -- it uses RNA, instead of DNA, to function.

This little bit of genetic material closely mimics a stretch of human RNA, they reported in the journal Nature Structural and Molecular Biology.

"We not only found the gene, but also a plausible explanation for why it is still there after millions of generations: its presence makes HIV dramatically better at reproducing inside of our cells," Bambara said in a statement.

"This suggests new ways to shut down with drugs the ability of the virus to mass produce copies of itself."

HIV is believed to have jumped to humans from a close relative called simian immunodeficiency virus or SIV, which infects chimpanzees.

"Feline immunodeficiency virus (FIV), which infects cats, is thought to be the virus from which SIV originated and therefore an ancestor of HIV," the researchers wrote.

"HIV-related viruses have been identified in sheep, goats, horse, cattle and cats, but only the cat virus FIV seems to be a close relative of HIV and SIV."

The gene Bambara's team found looks very much like human tRNALys, which HIV needs to replicate itself. Like all viruses, HIV "lives" by infecting cells, hijacking their machinery and turning them into factories that make copies of the virus.

"Determination of the origin of the tRNA-like sequence should provide valuable clues about the ancestry of HIV," the researchers wrote.

Studying this genetic sequence more may help scientists understand how viruses jump from animals to humans, added Matthew Portnoy of the National Institute of General medical Sciences, one of the National Institutes of Health.

The study "has broader implications beyond HIV research, and may impact the response to the current H1N1 flu pandemic, where that virus has jumped multiple species and picked up several parts of its genome from each of the many species it has passed through," Portnoy said in a statement.

"Understanding the mechanisms of these transfers enables researchers to better understand the evolution of viruses, and hopefully to better predict their 'next move' as they design vaccines and treatments," Portnoy said.

HIV now infects an estimated 33.4 million people, according to the United Nations, and has killed 25 million. H1N1 swine flu is still spreading globally and has infected tens of millions.

© Thomson Reuters 2009. All rights reserved.

[b9molecule]

Amarillo has a new website. lots of good info
http://www.amarbio.com/summary-of-the-safety-and-efficacy-of-interferon-for-influenza.html

[sludgehound]

1st US H1N1 in Va flock turkey farm

http://afludiary.blogspot.com/2009/11/us-turkey-farm-reports-h1n1.html

U.S. finds pandemic H1N1 virus in turkey flock
Mon Nov 30, 2009 5:53pm EST
WASHINGTON (Reuters) - The pandemic H1N1 flu virus was confirmed in a flock of breeder turkeys in Virginia -- the first U.S. case involving turkeys, the U.S. Agriculture Department said on Monday.

The virus also has been found in hogs, three house cats, pet ferrets and a cheetah in California. USDA said infections of turkeys have been reported in Canada and Chile.

"This is the first detection of 2009 pandemic H1N1 influenza in turkeys in the United States," said a USDA spokesperson.

"There is a possibility that a worker, who was sent home ill with flu-like symptoms, could have infected the turkeys as a result of the artificial insemination processes, as the worker was a member of the insemination crew."

USDA said people cannot get the flu from eating turkey meat.

Swine flu viruses are known to affect quails and turkeys periodically, said USDA. USDA's Agricultural Research Service conducted two studies this year to see if the H1N1 pandemic virus could affect turkeys or other domestic fowl. Five turkey samples collected in mid to late November contained the virus.

(Reporting by Charles Abbott; Editing by Marguerita Choy)

© Thomson Reuters 2009. All rights reserved

[cfoofme]

http://finance.yahoo.com/news/NanoViricides-Files-Quarterly-bw-3097875377.html?x=0&.v=1

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reports that the Company has filed its

The Company reported that it had $4.2 million in cash and cash equivalents as of September 30th, 2009. The Company previously reported that it had successfully raised a total of over $4.3M in different private placement instruments. The details have been disclosed in an SEC Form 8-K filed on October 5, 2009. The Company believes it has sufficient funds to last through the end of December, 2010 at the current rate of expenditure.

The Company now has four commercially important drugs in its pipeline, targeting a total market size of approximately $40 Billion. These drugs target HIV, all Influenzas, viral diseases of the external Eye, and Herpes Simplex viral infections including cold sores and genital herpes (HSV). In addition, the Company has R&D programs in collaborations with reputed institutions against several Neglected Tropical Diseases and agents of interest for Biosecurity. These include hemorrhagic fever viruses such as Ebola/Marburg, Dengue, and Rabies, among others.

Our current drug programs include a pan-influenza drug candidate, “FluCide™”. This drug was recently reported to be highly effective against H1N1 influenza in a lethal animal model, leading to an average 14 days survival. It is generally believed that a 14 day survival in this lethal challenge model would suggest indefinite survival in other standardized animal models. FluCide is designed to be effective against all influenza A strains and mutants. We anticipate FluCide to be effective against highly pathogenic avian influenzas such as H7 and H9, the epidemic bird flu virus H5N1 (various clades), the current novel H1N1/2009 virus, seasonal influenza viruses, and their mutations.

The Company has previously reported that its anti-HIV drug candidate was >25X (or >2,500%) more effective than the oral HAART treatment, on a drug load basis. This study employed a standard SCID-hu Thy/Liv mouse model. Human lymphocytes implanted in a mouse, and infected with HIV, are treated with antiviral drugs in this model. It is very important to note that no adverse events were observed in the nanoviricide treated mice, while the HAART-treated mice exhibited clinical signs of side effects. HAART or “highly active anti-retroviral therapy” is a three-drug combination therapy currently in use in human clinical practice, and is regarded as the most effective therapeutic regimen against HIV. If these preliminary results are confirmed in further animal studies and in human clinical trials, the Company believes that HIVCide™ could very well result in a “Functional Cure” for HIV/AIDS.

The Company has reported significant progress in its topical nanoviricide eye drops program. This drug is designed to treat most viral infections of the external eye, including adenoviral epidemic kerato-conjunctivitis (EKC) and herpes keratitis.

The Company also recently reported that it has successfully added a new anti-HSV drug program to its pipeline this year. The Company‘s topical anti-herpes drug candidate has already demonstrated greater than 10,000-fold (>99.99%, or >4 logs) reduction in virus quantity in cell culture models of HSV-1 infection. Animal model studies of topical and genital herpes are planned.

“We are now well poised to further develop our drug candidates

[cfoofme]

H1N1 virus mutation means no protection - swine flu vaccine ineffective against Ukraine flu outbreak

November 27, 8:35 AMLA Health Technology Examiner
Victoria Nicks

One sample of the Ukraine flu virus has been classed as a low reactor to the H1N1 vaccine. If this mutation spreads, it could result in infection for people who have been vaccinated against the swine flu. Other mutations that have been identified include Tamiflu resistance and complete destruction of the lungs.

Virus mutation and reaction to flu vaccines

Vaccines are created to respond to each different type of virus, and must be adapted if the virus changes too much from the original. Influenza viruses are highly susceptible to mutation, which explains the requirement for a new seasonal flu vaccine each year. When a vaccine provides a strong immune response to a virus, that virus is considered to be a high reactor to the vaccine. In the event that the virus mutates to the point where the vaccine provides a limited or nonexistent level of protection, it is considered a low reactor.

H1N1 mutation and the swine flu vaccine

The samples of the Ukraine flu virus that were analyzed by the World Health Organization provide a great deal of information about the mutations found in this strain of the swine flu. For example, each of the samples from fatalities contained a change in the receptor binding domain for the virus to D225G, which affects the lungs. In addition, one sample has been classed as a low reactor, which means that if that strain of virus were to spread, individuals who have been vaccinated would not be protected.

http://www.examiner.com/x-29228-LA-Health-Technology-Examiner~y2009m11d27-H1N1-virus-mutation-means-no-protection--swine-flu-vaccine-ineffective-against-Ukraine-flu-outbreak

[cfoofme]

China expert warns of pandemic flu mutation

http://www.reuters.com/article/healthNews/idUSTRE5AO16220091125

[cfoofme]

http://www.technologyreview.com/biomedicine/24001/

Arming the Immune System against H1N1
Researchers are working to treat pandemic flu by recruiting a patient's own immune cells.

[gym gravity]

interesting.

[b9molecule]

take a look at AMAR .19
in Australian clinical trials for interferon lozenge that mitigates or prevents all variants of the flu virus including H1N1. Think how quickly a throat lozenge can be distributed to help prevent infection, plus the added benefit of people not needing an injection.

caveat - the fundamentals currently stink, but if the trial is positive that could change quickly as a marketing partner is already in place. It's a good story at the right place and time.

links:
Amarillo Biosciences Reports on Research Supporting Use of Interferon to Combat Influenza
http://finance.yahoo.com/news/Amarillo-Biosciences-Reports-iw-1282275303.html?x=0&.v=1

Amarillo Biosciences Partners With Intas Pharmaceuticals to Treat Influenza in India
http://finance.yahoo.com/news/Amarillo-Biosciences-Partners-iw-1852917039.html?x=0&.v=1

Amarillo Biosciences' Phase 2 Australian Clinical Study of Interferon as a Preventative Agent Against H1N1 Flu Virus and Other Cold and Flu Viruses Reaches Midway Point
http://finance.yahoo.com/news/Amarillo-Biosciences-Phase-2-iw-949069498.html?x=0&.v=1

chart:


worth a flyer, IMO
GLTA

[cfoofme]

NanoViricides Presents FluCide™ Animal Study Data at Influenza Congress - Now Improved Substantially & Vastly Superior to C...





NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that Dr. Eugene Seymour, MD MPH, CEO of the Company, presented lifetime data from the recent FluCide™ animal study on November 19th at the Influenza Congress USA 2009 in Washington, DC (www.terrapinn.com/usaflu). These data clearly established that the new version of FluCide™ is superior to the older version. The data also showed extremely large survival lifetime improvement compared to an extended therapy using oseltamivir (Tamiflu® Roche).


Separately, Dr. Anil R. Diwan, President of the Company, presented a talk on November 18th at the Nano and Clean Tech 2009 Conference (http://www.chemshow.com/includes/nano.pdf) in New York City, held in conjunction and partnership with the Chem Show 2009 (http://www.chemshow.com).


Dr. Diwan gave a description of the nanomedicine technology on which the Company’s product platform is based. He then went on to discuss the successful development of several drug candidates in a relatively short timeframe and with very small R&D expenditures that NanoViricides Inc. has been able to achieve. “Our achievements have clearly demonstrated that we can develop drug candidates against new virus targets very quickly,” he said. He explained that the multi-point binding of a nanoviricide™, enabled by the underlying TheraCour® polymer, results in a nanoscale “velcro” or zipper-like effect. This allows the Company to employ virus-binding ligands with relatively low affinities successfully. “Other drug development approaches require discovery of antibodies or chemicals with very high affinities, sub-micromolar or better, which takes a lot of time and money,” he said, adding, “In contrast, our technology allows us to use mimics of the natural and conserved binding sites of the viruses. This allows rapid development. Also, it means that a virus is far less likely to escape a nanoviricide compared to its escape rate against a highly specific drug discovered using a conventional methodology.”

The recent animal study of FluCide was conducted using the same total lethality protocol employed in previous influenza studies by the Company. The new version of FluCide drug candidate extended the lifespan of lethally infected mice to 334±11 hrs (or 14 days) on average. In contrast, mice treated with an extended oseltamivir protocol survived for 193±3 hrs (or 8 days) on average. Control infected mice survived for only 121±2 hrs (or 5 days). FluCide was given as an IV injection, on alternate days, for five treatments. Oseltamivir was given as oral, twice daily, each at 20mg/kg through life (or 14 treatments). Previously, oseltamivir given using the customary protocol of oral, twice daily, each at 20mg/kg for 4 days (8 treatments), has produced a survival time of 151±1 hrs (or 6.3 days) in this model. Several additional parameters have been evaluated in this study. The Company expects to analyze the data from these additional parameters as they are received in the near future.


The Company believes that the lifetime data demonstrate an unquestionable superiority of the FluCide drug candidate compared to current drugs, and establish it as a viable therapy against influenza. We believe that FluCide is likely the most effective drug candidate in development against influenza, based on these results.


The studies were conducted by Dr. Krishna Menon, PhD, VMD, MRCS, at KARD Scientific, MA. One million virus particles of Influenza A Strain A/WS/33 (H1N1) were aspirated directly into the lungs of mice. A repeat “booster” infection was performed at 22 hrs. This is a highly lethal model, allowing the survival lifetimes to be directly used for rank ordering of efficacy of drug candidates.


The Company has previously shown that a previous version of the FluCide drug candidate was highly effective against two different clades of the H5N1 bird flu virus, in addition to being highly effective against H1N1 in the mouse model. The Company has recently improved the FluCide drug candidate, creating what it believes to be a single drug candidate against all forms of influenza. The Company believes that the data we presented at the Influenza Conference establish this pan-influenza drug candidate as a leading anti-influenza drug in development.

http://ih.advfn.com/p.php?pid=nmona&article=40470808&symbol=NNVC

[cfoofme]

H1N1 Mutation Appearing In Clusters

Written by Staff and Wire Reports
Saturday, 21 November 2009 00:00
http://biomedreports.com/articles/most-popular/18952-h1n1-mutation-appearing-in-clusters.html

[NYBob]

EX-HEALTH MINISTER OF FINNLAND MAKING EYE-AWAKING STATEMENTS
(on the flu)

Robert F. Kennedy Jr. On the Vaccine Cover Up -

http://www.infowars.com/flashback-robert-f-kennedy-jr-on-the-vaccine-cover-up/

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=43341765

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=43343672

http://www.888c.com/
God Bless

[User-65225]

Pacific Sands, Inc. Announces Green Living Expert Annie B. Bond's Natural Flu Protection Kit Now Available at EcoGeeks.com

Learn How to Kill Germs in the Home or Office Using Methods and Products That Are Government-Approved, but That Won't Harm Your Health...or the Environment

* Press Release
* Source: Pacific Sands, Inc.
* On 3:10 pm EST, Friday November 20, 2009

*
Companies:
o Pacific Sands Inc.

RACINE, WI--(Marketwire - 11/20/09) - Pacific Sands, Inc. (OTC.BB:PFSD - News) is pleased to present The Natural Flu Protection Kit, (now available at www.EcoGeeks.com) the first product to emerge from the company's partnership with Annie B. Bond and GreenChiCaf?.com.

Annie B. Bond is called the foremost expert on green living by Body & Soul Magazine, and is the best-selling author of five books, including "Clean & Green," "Better Basics for the Home," and "Home Enlightenment."

The Natural Flu Protection Kit includes an eco-friendly disinfectant that has the lowest toxicity rating and is approved by the Environmental Protection Agency (EPA), and an EPA-approved 100 percent botanical disinfectant. The kit also includes an alcohol-based hand sanitizer as recommended by the Centers for Disease Control (CDC), but Annie's uses no Triclosan (a suspected endocrine disruptor found in every dolphin tested in an area off the coast of Florida); it is instead enhanced with essential oils.

"Nobody wants the flu, but we also don't want to poison our homes with toxic chemicals while trying to kill germs," notes nontoxic living expert, Annie B. Bond. With this in mind, she has assembled what she considers the safest government-approved products to kill germs and to protect families throughout flu season.

In the Natural Flu Protection booklet, Annie shares what she has learned in over two decades of research into nontoxic living. Just like with antibiotics, when overused, disinfectants can lead to "superbugs;" bacteria that are impervious to all our efforts to kill them. Essential oils are not thought to cause this problem, and Annie shows how to use them effectively, with information on how long viruses survive on surfaces and tips on commonsense practices.

"It is important to protect against illness, especially in the face of a global flu pandemic," Annie added. "This task is made more difficult by the level of hysteria that has been whipped up by many. In the face of alarming headlines and emergency government tactics, some people douse every surface of their homes with caustic bleaches and industrial-strength cleaners. Not only is this futile -- no home can truly be made sterile -- it also pollutes living quarters with potentially dangerous and toxic chemicals."

With the Natural Flu Protection Kit, Annie Bond addresses these concerns, giving people tools to kill germs, while safeguarding them against noxious chemicals. In the booklet she offers formulas and tips for do-it-yourself home and personal spritzers using essential oils (tea tree, eucalyptus, oregano, etc.) that while they aren't government certified, they come with proven antifungal, antibacterial, antiviral and antiseptic properties. She also explains other plant-based materials (vinegar, witch hazel, aloe vera) that are effective in killing germs, molds and viruses, but are not harmful to people and animals.

Annie B. Bond's Natural Flu Protection Kit is a compact storehouse of powerful, natural antiviral protection that is safer for health and the planet. It is available at: http://www.naturalfluprotection.com or http://www.ecogeeks.com.

For additional information visit http://www.greenchicafe.com.

To request an eBook copy of The Natural Flu Protection and a blog for your use, write pr (at) www.greenchicafe.com.

About Pacific Sands, Inc.: Pacific Sands, Inc. manufactures, markets and sells a broad range of environmentally-friendly products. The partnership is designed to provide information, products, and inspiration for helping people put the green lifestyle into practice.

Safe Harbor Act Disclaimer

The statements contained in this release and statements that the company may make orally in connection with this release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected in the forward-looking statements, since these forward-looking statements involve risks and uncertainties that could significantly and adversely impact the company's business. Therefore, actual outcomes and results may differ materially from those made in forward-looking statements.
Contact:



Contact:
Annie Bond
GreenChiCaf?.com Media and Business Contact:
Renee Rush
262-880-8276
[e-mail]
Pacific Sands Investor Relations:
Ray Sweezy
860-922-8883
http://www.PacificSands.biz

[sludgehound]

Norway scientists concern mutated form of swine flu

News Alert
10:47 AM EST Friday, November 20, 2009

Norwegian scientists raise concerns about mutated form of swine flu

A mutated form of the virus has been found in two patients who died and one who became severely ill, but scientists say it does not appear to be circulating in the general population.

For more information, visit washingtonpost.com - http://link.email.washingtonpost.com/r/LI37JS/PIPV9/PRMHDF/9Y7Z8I/QLRAV/CM/t

[cfoofme]

Experts say radical measures won't stop swine fluBy MARIA CHENG, AP Medical Writer – 31 mins ago
http://news.yahoo.com/s/ap/20091119/ap_on_he_me/eu_med_swine_flu_tough_measures;_ylt=AkRfRuGdt_SiDYnD3Iiwa5tvaA8F;_ylu=X3oDMTM0NWh1MGZmBGFzc2V0A2FwLzIwMDkxMTE5L2V1X21lZF9zd2luZV9mbHVfdG91Z2hfbWVhc3VyZXMEcG9zAzcEc2VjA3luX2FydGljbGVfc3VtbWFyeV9saXN0BHNsawNleHBlcnRzc2F5cmE-
LONDON – Health experts say extraordinary measures against swine flu — most notably quarantines imposed by China, where entire planeloads of passengers were isolated if one traveler had symptoms — have failed to contain the disease.
Despite initially declaring success, Beijing now acknowledges its swine flu outbreak is much larger than official numbers show.
China's official count of nearly 70,000 reported illnesses with 53 deaths dwarfs estimates of millions of cases with nearly 4,000 deaths in the United States, a nation with about a third of China's population.
Dr. Michael O'Leary, WHO's top representative in China, says there has been a dramatic spike in Chinese swine flu cases recently and those reported by the government are only "minimum numbers."
"We have new cases occurring all the time," he told The Associated Press last week. "There's always more deaths than we could possibly know about."
He said there is little data to prove interventions like mass quarantines and school closures slow down disease transmission. "To draw a causal link ... is not always possible," O'Leary said, adding that WHO expected a disease as contagious as swine flu to spread regardless of what measures countries impose.
China's Health Minister Chen Zhu defended his country's aggressive quarantine policy, telling the AP on Wednesday that the measures helped slow the spread of the virus long enough for China to develop a vaccine, which authorities are now scrambling to administer.
"With initial efforts of containment, actually we not only reduced the impact of the first wave to China, but we also won time for us to prepare the vaccine," Chen said in an interview on the sidelines of a meeting of the Global Forum for Health Research in Havana.
He said China was vaccinating 1.5 million people a day against swine flu as part of a massive effort to try to reach as many as 90 million people — about 7 percent of the country's population — by the end of the year.
"We know this is not enough for a population of 1.3 billion, but at least for the vulnerable people, for the students, people with underlying basic diseases and ... for pregnant women, we have vaccines," Chen said.
On Thursday, Dr. Zhong Nanshan, director of Guangzhou's Institute of Respiratory Diseases, said in a local newspaper he believed government officials were covering up swine flu deaths to appear as though their handling of the epidemic had been successful.
"I totally don't believe the current number of swine flu deaths that have been reported in the country," Zhong said in Guangzhou Daily. He was one of the doctors who openly challenged China's 2003 cover-up of its outbreak of Severe Acute Respiratory Syndrome.
China has acknowledged swine flu is now widespread despite its aggressive attempts at containment.
Earlier this month, Feng Zijian, head of China's Center for Disease Control and Prevention, said the country's reported figures are only "a very small portion" of the total number of cases.
He said China is now focusing on confirming severe cases and no longer tests every person with a fever for swine flu. He said the official figures were based on cases confirmed in outbreaks or at monitoring sites like hospitals.
Other nations that have carried out draconian swine flu policies indicate they have little effect in containing the disease.
Ukraine, which reported more than 250,000 suspected cases last week, closed all schools and universities, and advised people not to travel and to stay away from public places. In Mongolia, all bus travel has been suspended and gatherings of more than 40 people have been banned. Still, both countries are now facing major swine flu outbreaks.
Argentina, Singapore, Malaysia and Egypt have also enacted radical swine flu prevention measures — and all have been gripped by widespread outbreaks.
When WHO declared swine flu to be a pandemic in June, it described the virus as "unstoppable." It advised countries not to close their borders or impose mass quarantines, warning such measures would be useless since people often spread flu viruses before developing any symptoms.
China is no exception, scientists say.
"China did not keep the virus out. They failed," said Dr. Michael Osterholm, director of the Center for Infectious Diseases Research and Policy at the University of Minnesota.
He said he believes the actual number of swine flu cases is "far in excess of what China is reporting," based on the center's own network of official and unofficial sources in the country.
Some experts say the relatively small size of China's reported outbreak is suspicious given that neighboring regions are battling huge epidemics. Last week, WHO said Mongolia, which borders China, was reporting its health system was being crushed by swine flu cases.
In Hong Kong, a city of 7 million on China's southern coastline, authorities have reported 40 swine flu deaths, compared to the 53 reported in China.
"The issue in China has to do with surveillance," said Sandra Mounier-Jack, a flu expert at the London School of Hygiene and Tropical Medicine. Because swine flu symptoms are so vague, many cases are being missed in China, as they are everywhere, she said.
WHO and the U.S. Centers for Disease Control and Prevention gave up counting swine flu cases months ago when the virus became widespread.
Past disease outbreaks also give experts reason to question China's numbers. In 2003, China covered up an epidemic of Severe Acute Respiratory Syndrome, which ultimately killed about 800 people when it spread worldwide.

[sludgehound]

4 bits: UK, Lithuania, 30% rhinovirus, Germany 2X

http://www.reuters.com/article/healthNews/idUSTRE5AH25620091118?feedType=nl&feedName=ushealth1100
LONDON (Reuters) - More than half of Britons being offered vaccination against pandemic H1N1 flu are turning it down because they fear side-effects or think the virus is too mild to bother, a survey of doctors showed on Wednesday.
<more>
-----------
And Lithuania reported first death from swine flu today said a
Bloomberg flash.
-----------
http://www.reuters.com/article/healthNews/idUSTRE5AG52F20091117?feedType=nl&feedName=ushealth1100

WASHINGTON (Reuters) - Runny nose, fever, cough, even pneumonia -- the symptoms sound like swine flu but children hospitalized at one U.S. hospital in fact had a rhinovirus, better known as a common cold virus, doctors said on Tuesday.
<more>
----------
German H1N1 flu cases double in a week: authority
Mon Nov 16, 2009 6:00am EST
BERLIN (Reuters) - Confirmed cases of H1N1 swine flu infection in Germany have more than doubled in the past week, the Robert Koch Institute (RKI) for infectious diseases said.

"We now have more than 15,000 reported new cases per week -- and those are just the ones confirmed in the laboratory," the RKI's Gerard Krause told ZDF television on Monday.

Last Wednesday the institute said "about 7,000" new cases were being identified in Europe's largest economy per week.

As of last week, 16 people had died from the flu in Germany, with more than 50,000 infected, according to the institute.

The H1N1 virus has spread to over 200 countries, and caused more than 6,250 deaths to date, mostly in the Americas region, according to the World Health Organization.

(Writing by Dave Graham; Editing by Matthew Jones)

© Thomson Reuters 2009. All rights reserved

[cfoofme]

CEL-SCI Announces Start of First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patientshttp://ih.advfn.com/p.php?pid=nmona&article=40416578&symbol=AMEX:CVM&cb=1258555579

[webpence]

Swine Flu Virus Created from Pig Vaccine?

The swine flu virus had three parents from two continents and appeared suddenly without warning, evading all routine flu surveillance and quarantine; sequence data suggest it may have been created from a faulty vaccine given to pigs in North America Prof. Adrian Gibbs and Dr. Jean Downie

This report has been submitted to the US FDA and CDC, and to Sir Liam Donaldson, UK’s Chief Medical Officer

MATERIAL ON THIS SITE MAY NOT BE REPRODUCED IN ANY FORM WITHOUT EXPLICIT PERMISSION. FOR PERMISSION, AND REPRODUCTION REQUIREMENTS, PLEASE CONTACT ISIS. WHERE PERMISSION IS GRANTED ALL LINKS MUST REMAIN UNCHANGED

Background
Several papers reporting phylogenetic analyses of the gene sequences of the new pandemic swine-origin H1N1 virus (S-OIV) have been published. All show that S-OIV inherited its genes from parents that came from two well-known groups of swine flus. Flu viruses have 8 different genes and in mixed infections sometimes shuffle those genes to form ‘reassortants’ with new combinations of the 8 genes chosen from those of the parents. Several reports have shown that six of the genes of S-OIV came from a ‘triple-reassortant’ influenza virus (or viruses). These viruses have been common in North American pigs for more than a decade, and have never been found in Europe. The other two genes (NA and MP) came from Eurasian ‘avian-like’ viruses common in Europe for longer, but never found in North America. Both groups of viruses have however been found recently in pigs in SE Asia.

The analyses reveal an unusual feature of the S-OIV genes, which is that none of the genes have been found recently in swine influenzas collected during routine flu surveillance. The NA gene had not been sampled (identified in samples) for 17 years before it reappeared in S-OIV, and the others, including the MP gene, for around 11 years. Thus the NA and MP genes were most likely acquired by S-OIV from Eurasian ‘avian-like’ viruses on separate occasions, and therefore S-OIV probably had at least three parents.

We have done further specific analyses to find out which isolates contain the genes that are closest to those of S-OIV. We find that all are viruses of pigs. The NA gene of S-OIV is closest to that of European ‘avian-like’ H1N1 influenza viruses sampled in 1991/1993, its MP gene closest to that of H3N2 Asian ‘avian-like’ viruses sampled in 1999, and its other six genes are closest to those of North American H1N2 ‘triple-reassortant’ viruses sampled in 1999/2000. Note that the dates those isolates were collected agree with the calculated ‘time-line’ leading to S-OIV; NA 17 years ago, all the others 11 years.

In summary, S-OIV is a reassortant with at least three parents. The parents were sampled over a decade ago, all found in pigs, and in three very distant parts of the world; North America, Europe and SE Asia!!!

http://www.i-sis.org.uk/swineFluVirusFromPigVaccine.php

[webpence]

Where Did the H1N1 Late-2009 Flu Season Virus Come From?

If your understanding is the current H1N1 late-2009 season flu pandemic began in Mexico as it spread from herds of pigs to humans there you are probably among the millions who have been misled as to the origins of this flu outbreak.

Only one group of virologists that I could find has asked the right questions and has properly investigated the origins of the H1N1 swine flu virus of 2009. Yet even these virologists are off the mark when it comes to understanding the current flu pandemic.

Professor Adrian Gibbs and Dr. Jean Downie, virologists writing at the Institute of Science in Society, provide much of the following data for the origins of the current late-season flu outbreak that is sweeping the globe.

It is easy to get confused when reading about H1N1 flu viruses. When referring to H1N1 flu variants, these do not necessarily refer to the triple reassortant H1N1 late-2009 flu virus that is completely novel and unprecedented. The Spanish Flu of 1918 was an H1N1 flu variant, but not the exact variant currently in circulation. These flu variants need to be distinguished from each other.

Furthermore, pay careful attention here because the H1N1 late-2009 season flu virus is now the prevalent flu virus in circulation in the North American population and for unexplained reasons the seasonal flu threat has ceased to exist, at least at the date of writing this report (Sept. 24, 2009). The seasonal flu has vanished this year.

Here are the facts surrounding an investigation into the origins of the H1N1 swine flu of 2009 as Professor Gibbs and Dr. Downie present them, along with cited references to other important facts I uncovered in my own investigation:

The swine flu virus of 2009 appeared suddenly and without warning, and evaded all routine flu surveillance and quarantine.
This flu is not like other flu viruses seen in the past. It is a triple-reassortant flu virus.
Examination of the longer phylogenetic branch length compared to its nearest genetic neighbors indicates that the appearance of this novel H1N1 swine flu virus of 2009 is unlikely to be a recent event. [Virus Genes, early online, August 20, 2009] But this would mean it had to be in circulation for many years, for which there is no evidence. However, a long development period assumes natural variation and gene mutation rates, not mutations induced by artificial means, or the actual creation of this virus in a laboratory and subsequent instillation into human populations.
Six of this flu virus’ genes came from a "triple-reassortant" influenza virus (or viruses).
These viruses were found in North American pigs more than a decade ago, then completely disappeared, and have never been found in Europe. The other two genes came from Eurasian "avian-like" viruses common in Europe for longer, but never found in North America. However, both groups of H1N1 viruses have been found recently in pigs in southeast Asia.
Movement of live pigs between Eurasia and North America may have facilitated mixing of diverse swine influenzas, leading to the multiple reassortant events. This goes unquestioned. But there is a strong reason to think the possibility of swine-to-human transmission is a misdirection.
While pigs are exported from one country to another, they are exported from North America to Asia, not the other way around.
Strict quarantine measures are employed when pigs are exported so as not to contaminate an existing herd with disease. Usually imported pigs are kept in quarantine, away from a larger herd, for a period of two weeks. If an imported herd brought a suspect gene sequence with it, it would have had to somehow evade quarantine measures.
The development of this virus would require at least two trans-continental trips to get together in one place, and hence this theory requires at least two quarantine failures, probably three say Drs. Gibbs and Downie. This is not likely.
None of the genes found in this swine influenza had been in current circulation. The NA (nearuaminidase) gene had not been identified in samples for 17 years before it reappeared in early 2009, and the others, including the MP gene, for around 11 years. Drs. Gibbs and Downie say this suggests the virus emanated from a swine herd vaccine. Or it could have emanated from an accidental release from an infected human working at a vaccine plant, or it was intentionally induced into human populations in Mexico.

http://www.lewrockwell.com/sardi/sardi122.html

[webpence]

Deadly flu spreads across Ukraine

"Over the past two weeks, what appears to be a particularly virulent form of the flu has been spreading in Ukraine and adjacent Eastern European countries. This new flu is, in my opinion, a lethal new strain which has mutated (or was released). I speak with a background in virology. This new mutated flu virus appears to have a remarkable affinity for the lungs and is causing deaths to a much higher extent than the previous swine flu. Something in the virus has changed. I have covered this incredibly important story for two weeks now in my weekly column This Week In Mayhem, which is generally published on Monday mornings."

Read more here...
http://www.zerohedge.com/article/deadly-flu-spreads-across-ukraine?

[webpence]

Low Vitamin D Levels Linked To Proliferation of H1N1

According to a recent study, as many as 77 percent of all Americans may be deficient in the vitamin essential for bone health and which may prevent H1N1 (Swine Flu) and seasonal flu, wheezing, winter-related eczema, upper respiratory infections and may help prevent cancer, autoimmune diseases such as multiple sclerosis, Type 1 diabetes, certain infectious diseases, myocardial infarctions – heart attacks – and many other serious diseases.

When subgroups of the population are considered, depending on which of the many reasonable definitions of deficiency are accepted, the picture is even more ominous. For example, an important new study from Children's Hospital in Boston found that as many as 80 percent of Hispanic children and 92 percent of black children, what the study calls non-Hispanic black children, may also be deficient in this vitamin.

We're talking about vitamin D, also called the sunshine vitamin and often considered the nutrient of the year, if not the decade. Its power as a determinant of human health can be captured by what happens when someone is D deficient. They are at risk for what is called rickets in children and osteomalacia in adults.

In its most extreme form, the bones soften and almost melt, making them so fragile that the simple act of walking up steps may cause bones to fracture and slight movement may cause excruciating pain. In its most severe form, a blood test for vitamin D may show zero. Dr. Fred Kaplan, an eminent orthopedic surgeon at the Hospital of the University of Pennsylvania, whose patient had zero D, said this is rare even in Third World countries.

Why, in the land of plenty and, now, also in the land of over-consumption, overweight and obesity, can there be an epidemic of a vitamin D deficiency or any other nutrient? The reasons may not be fully understood, but the picture is still clear: Over time, we have obtained most of our vitamin D from the sun. When ultraviolet B rays hit the skin they cause the formation of vitamin D. But, in an age of sunscreens and well-placed fear of skin cancer, we tend to either stay out of the sun or use a sunscreen to shield us from its rays, including the ultraviolet B ray.

http://preventdisease.com/news/09/111609_H1N1_linked_vit_D_deficiency.shtml

[Rawnoc]

REPR related....

Swine Flu Test Kit Shortage
http://www.tpr.org/news/2009/04/news0904291.html

Global pharma cos to ramp up test kit production
"This means diagnostic chains such as Dr Lal PathLabs, Super Religare Labs (formerly SRL Ranbaxy), Quest Diagnostics, Metropolis and Dr Dang Labs may soon start buying these kits in bulk, once they get the government approval."
http://economictimes.indiatimes.com/News/News-By-Industry/Healthcare/Biotech/Pharmaceuticals/Global-pharma-cos-to-ramp-up-test-kit-production/articleshow/4891805.cms

Swine Flu Pandemic Kits - 3 Key Reasons Why You Need One Now
http://www.articlesbase.com/wellness-articles/h1n1-flu-pandemic-kits-its-not-too-late-to-protect-yourself-1452156.html

[User-65225]

PFSD just became a swine flu stock with the introduction of their new product and marketing partnership...

The company is fully filing, low float, VERY responsible with dilution and they just broke $1,000,000 revenue. All with a market cap of about 2,000,00...

This PR was not mass disseminated, but i think they are going to rerelease it through the major services, along with more details on the product... This play is VERY under the radar....

Green Living Expert Annie B. Bond's Natural Flu Protection Kit
Wed. November 11, 2009; Posted: 03:04 AM

Are you looking to increase your ETF knowledge?
Rhinebeck, NY, Nov 11, 2009 (PRWeb.com via COMTEX) -- PFSD | Quote | Chart | News | PowerRating -- Pacific Sands, Inc (OTCBB: PFSD | Quote | Chart | News | PowerRating) is pleased to present The Natural Flu Protection Kit, the first product to emerge from the company's partnership with Annie B Bond and GreenChiCafe.com.
Annie B. Bond is called the foremost expert on green living by Body & Soul Magazine, and is the best-selling author of five books, including Clean & Green, Better Basics for the Home, and Home Enlightenment. Pacific Sands, Inc. manufactures, markets and sells a broad range of environmentally-friendly products. The partnership is designed to provide information, products, and inspiration for helping people put the green lifestyle into practice.

The Natural Flu Protection Kit includes an eco-friendly disinfectant that has the lowest toxicity rating and is approved by the Environmental Protection Agency (EPA), and an EPA-approved 100 percent botanical disinfectant. The kit also includes an alcohol-based hand sanitizer as recommended by the Center for Disease Control (CDC), but Annie's uses no Triclosan (a suspected endocrine disruptor found in every dolphin tested in an area off the coast of Florida); it is instead enhanced with essential oils.

"Nobody wants the flu, but we also don't want to poison our homes with toxic chemicals while trying to kill germs," notes nontoxic living expert Annie B. Bond. With this in mind, she has assembled what she considers the safest government-approved products to kill germs and to protect families throughout flu season.

In the Natural Flu Protection booklet, Annie shares what she has learned in over two decades of research into nontoxic living. Just like with antibiotics, when overused, disinfectants can lead to "superbugs;" bacteria that are impervious to all our efforts to kill them. Essential oils are not thought to cause this problem, and Annie shows how to use them effectively, with information on how long viruses survive on surfaces and tips on commonsense practices.

It is important to protect against illness, especially in the face of a global flu pandemic. This task is made more difficult by the level of hysteria that has been whipped up by many. In the face of alarming headlines and emergency government tactics, some people douse every surface of their homes with caustic bleaches and industrial-strength cleaners. Not only is this futile-no home can truly be made sterile-it also pollutes living quarters with potentially dangerous and toxic chemicals.

With the Natural Flu Protection Kit, Annie Bond addresses these concerns, giving people tools to kill germs, while safeguarding them against noxious chemicals. In the booklet she offers formulas and tips for d.i.y. home and personal spritzers using essential oils (tea tree, eucalyptus, oregano, etc.) that while they aren't government certified, they come with proven antifungal, antibacterial, antiviral and antiseptic properties. She also explains other plant-based materials (vinegar, witch hazel, aloe vera) that are effective in killing germs, molds and viruses, but are not harmful to people and animals.

Annie B. Bond's Natural Flu Protection Kit is a compact storehouse of powerful, natural antiviral protection that is safer for health and the planet.

To request an eBook copy of The Natural Flu Protection and a blog for your use, write pr (at) greenchicafe (dot) com.

The statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

###

Read the full story at http://www.prweb.com/releases/anniebbond/naturalfluprotection/prweb3180414.htm.


PRWeb.com

For full details for PFSD click here.

[cfoofme]

NanoViricides, Inc. to Present Anti-Influenza Drug Candidate FluCide Studies at the Influenza Congress 2009

http://finance.yahoo.com/news/NanoViricides-Inc-to-Present-bw-755360621.html?x=0&.v=1

[cfoofme]

D.C. Vaccine Conference Attracts Government Policy Makers and Biotech Innovators
8:26a ET November 9, 2009 (Business Wire)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, reports that On Monday and Tuesday of this week, the 7th Annual Vaccines: All Things Considered Conference is taking place in Washington, DC. Investors should keep an eye on this event, which serves as a one-stop destination for valuable updates and exposure on all aspects of vaccine research, development, regulations, and policy via key, intimate presentations by innovative biotech companies and government regulators.

Organizers aim to provide exposure to all avenues of vaccine research, development, regulations and policy and updates on the flu pandemic, bio-defense policy. The National Vaccine Plan will also be addressed and discussed.

Several government officials, including representatives from the United States Department of Health and Human Services, National Research Council of Canada, National Institutes of Health, National Institute of Allergy and Infectious Disease, and the Food and Drug Administration, come together at this conference with representatives from several key biotech and pharmaceutical companies.

"The research and discovery of vaccines to fight globally prevalent diseases has been a major focus of the pharmaceutical industry's biggest players for decades," say members of the conference's organizing committee. "The pharmaceutical world has recently been rocked by the pending expiration of patents on several major block-buster drugs. How does this affect funding for vaccine research and development? What will be the path forward? How will the generic drug industry affect the vaccines market? These are just a few of the questions the Vaccines conference will address and answer."

Scheduled to present the event's opening remarks and to moderate several of the key presentation sessions is Dr.Daniel Zimmerman, Ph.D., Senior Vice President Research and Development, Cellular Immunology for CEL-SCI Corporation (AMEX:CVM). Zimmerman's work at the company in partnership with several research university partners has been attracting a great deal of attention in both the H1N1 influenza and inflammatory disease space lately.

Companies who will share the spotlight in front of some of the key officials from the government agencies include:

Ibis Biosciences, Inc., Immunovaccine, Inc.(CVE:IMV), Advaxis, Inc.(OTC:ADXS) , EpiVax, VaxArt, VaxDesign, and at least three big pharmaceutical companies including Novartis (NYSE:NVS), Sanofi Pasteur, and Merck (NYSE:MRK).

Representatives from the academic research field will include:

Dr. Kenneth S. Rosenthal, Ph.D., ProfessorMicrobiology/Immunology, Northeastern Ohio Universities Colleges of Medicine and Pharmacy

Pirouz DaftarianHead, Biological Modifiers Laboratory, University of Miami

The complete report is available now at BioMedReports.Com:

http://biomedreports.com/articles/most-popular/17010-dc-vaccine-conference-attracts-government-policy-makers-and-key-biotech-innovators.html

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/fda-calendar/fda-calendar.html

About BioMedReports.Com

BioMedReports.Com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies.

For more biomedical sector and investment news go to http://BioMedReports.com

SOURCE: BioMedReports.Com

BioMedReports.Com
M. Davila, [phone]
Fax: [phone]
Assistant Editor
[e-mail]

[gym gravity]

Ukraine has notorious vitamin d deficiency.

[webpence]

Bulgaria Health Ministry Declares National Swine Flu Epidemic
Society | November 6, 2009, Friday


The Bulgarian Health Ministry has declared a national swine flu epidemic. Photo by BGNES
Bulgaria's Health Ministry announced Friday afternoon the declaration of a state of national swine flu epidemic over the rising number of patients with A(H1N1).

The Health Ministry made the decision based on the grounds that the number of people with swine flu has reached 210 per 10 000.

Thus, all schools in Bulgaria will be in a swine flu break all of next week (9-14 November). The Health Ministry recommends limiting the number and scope of public events.

Any decisions for closing nursery schools and universities over the epidemic will be made on the local level.

There will be no mandatory closing of cinemas, theaters, libraries, or other public facilities despite the declaration of a national epidemic.

The news from the Health Ministry came shortly after the Bulgarian capital Sofia declare a swine flu epidemic starting Monday. Thus, 20 of Bulgaria’s 28 administrative districts had declared swine flu epidemic before the news for the national emergency.

http://www.novinite.com/view_news.php?id=109698

[webpence]

Most Who Want Swine Flu Shot Can't Get It

Related News from HealthDay
• Most Who Want Swine Flu Shot Can’t Get It
• Health Fears Are Nothing to Sneeze At
• Swine Flu Virus Dominant Strain Worldwide: WHO
• Rest Easy. When It Comes to Swine Flu, Your Pet Is Safe
• Germs Mingle Most on Palms, Feet, Forearms
• FDA Initiative Seeks to Reduce Accidental Overdoses
Health News Archives


FRIDAY, Nov. 6 (HealthDay News) -- Although the total doses of H1N1 swine flu vaccine available in the United States now tops 38 million -- 11 million more than a week ago -- most Americans who want a shot still haven't been able to get one, U.S. health officials acknowledged Friday.

In fact, 70 percent of adults and 66 percent of children who tried to get vaccinated couldn't, according to a poll conducted last weekend by researchers at Harvard University School of Public Health.

"I think it was understandable that people were finding it difficult for people to find vaccine at the time of the poll, because we were and still are at a point where the supply is relatively limited, compared with the demand," Dr. Anne Schuchat, director of the National Center for Immunization and Respiratory Diseases at the U.S. Centers for Disease Control and Prevention said during a news conference Friday.

One positive finding of the Harvard poll was that nine out of 10 people said they would try again to get vaccinated, she noted. "They weren't giving up. They weren't so frustrated that they had had it. They recognized the value of protecting themselves with vaccine, and sticking with it through the next several weeks."

Schuchat noted the vaccine supply would continue to increase and next week an additional 8 million doses are expected. However, she was cautious in making any predictions about vaccine supply beyond next week.

"I am expecting in the next several weeks things will get better and better," she said. "But, we have all been burned on predictions, so I am not going to get more specific than that."

As demand for both H1N1 swine flu vaccine and the seasonal flu vaccine has reached unprecedented levels, the H1N1 strain continues to circulate and is widespread in 48 states.

More people are being hospitalized and confirmed deaths from swine flu among children have reached 129, according to the CDC. Of these children, two-thirds had underlying medical conditions such as cerebral palsy, muscular dystrophy and asthma, Schuchat said.

http://www.ajc.com/health/content/shared-auto/healthnews/flu-/632921.html

[webpence]

CDC: H1N1 Vaccine Supply Increasing, But Shortage Remains
Article
EmailPrinter
FriendlyShare:
facebook
↓ More
Text

By Jennifer Corbett Dooren
Of DOW JONES NEWSWIRES

WASHINGTON (Dow Jones)--Supply of H1N1 or swine flu vaccine is starting to increase although federal health officials acknowledge far more people want vaccine than can get it.

"Today we have twice as much vaccine as we did two weeks ago," said Anne Schuchat, the director of the Centers for Disease Control and Prevention's National Center for Immunization and Respiratory Diseases. She said more than 38 million doses of vaccine are available for states to order. As of Wednesday, 26.2 million doses had been shipped to states.

Health officials had once hoped more than 100 million doses would have been available by now, but manufacturers haven't been able to produce the vaccine as fast they predicted largely because the virus used to produce the vaccine hasn't grown well.

Officials recommend that children and young adults receive the H1N1 vaccine, along with pregnant women, health-care workers and anyone with chronic health conditions.

Although millions of Americans have had H1N1 influenza, a vaccine is still recommended for those in priority groups because most people who've had an influenza-like illness weren't tested to see what type it was.

Schuchat said another eight million vaccine doses should be ready by the end of next week, a slight drop from the 10 million to 11 million doses made available the past two weeks. She wouldn't make projections beyond next week.

As has been the case since the summer, nearly all influenza viruses circulating in the U.S. are the H1N1 virus, according to the CDC. Viruses that cause seasonal flu often aren't detected until December.

Illnesses from H1N1 influenza remains "widespread" in 48 states as of Oct. 31, the CDC said in its weekly influenza report that's released each Friday.

The agency said 18 pediatric deaths were reported last week with 15 of the deaths attributed to H1N1 and three to an influenza A virus that wasn't subtyped. Since April 26, CDC has received reports of 129 pediatric deaths from H1N1 and another 15 from influenza with an undetermined flu virus subtype. There's been at least 672 deaths in all age groups since Aug. 30, CDC said, and more than 18,000 hospitalizations attributed directly to the swine flu.

Schuchat said two-thirds of children who've died from the H1N1 virus had an underlying condition such as asthma or a neurological condition like cerebral palsy or muscular dystrophy.

Along with H1N1 vaccine, the seasonal influenza vaccine is also hard to find in many areas of the U.S.

Schuchat said about 91 million seasonal vaccine doses have been shipped out of about 114 million that are expected to be made. The private sector controls seasonal-flu vaccine distribution while the CDC is overseeing H1N1 vaccine distribution.

-By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294; [e-mail]

http://online.wsj.com/article/BT-CO-20091106-714305.html

[webpence]

Ukraine official says poll may be delayed by H1N1
Fri Nov 6, 2009 2:32pm EST Email | Print | Share | Reprints | Single Page [-] Text [+]
Featured Broker sponsored link

* Presidential aide says state of emergency could be called

* Follows Yushchenko's criticism of govt handling of flu

* Over 750,000 people ill with flu, over 30 with H1N1 strain



(Adds details)

KIEV, Nov 6 (Reuters) - Ukraine could delay a January presidential election until May next year if the government fails to control an outbreak of H1N1 flu, a senior official wrote on the respected news Web site Ukrainska Pravda on Friday.

In an opinion piece Ihor Popov, the deputy head of President Viktor Yushchenko's secretariat, accused Prime Minister Yulia Tymoshenko's government of being taken unawares by a flu epidemic and said a state of emergency could be called.

Yushchenko and Tymoshenko have hurled bitter recriminations at each other over the past 18 months. Both will run in the first presidential election since the 2004 "Orange Revolution" swept the two former allies to power.

"We hope that the government is able to manage the epidemic without a state of emergency," Popov wrote.

But he said measures already introduced such as a ban on public gatherings including political rallies raised questions about how fair an election would be.

"With more than two months to voting, it is completely possible to overcome the first wave of the (H1N1) flu and avoid another wave," he wrote.

"But should there be a state of emergency, the election would have to be delayed," he said, adding that May 30 would be an alternative date. The election is due to take place on Jan. 17, 2010.

mORE...
http://www.reuters.com/article/africaCrisis/idUSL695938

[webpence]

NYC Commissioner Defends Giving H1N1 Shots to Goldman (Update2)
Share Business ExchangeTwitterFacebook| Email | Print | A A A
By Pat Wechsler


Nov. 6 (Bloomberg) -- New York City Health Commissioner Thomas Farley said his department sent 6 percent of the city’s limited doses of swine flu vaccine to Citigroup Inc., Goldman Sachs Group Inc. and other large employers because they traditionally distribute shots in flu seasons.

As many as one-quarter of adults who receive seasonal flu shots get them at work, Farley said today in an interview on CNBC. He said he understands the frustration people are feeling because they can’t get the vaccine. City clinics, open Saturdays to vaccinate middle-school and high-school students, also will provide shots to pregnant women tomorrow, Farley said.

The disclosure about the vaccine distribution to private employers in New York spurred the White House and top officials to reinforce U.S. health guidelines calling for children, pregnant women and adults with serious health conditions to be among the first to receive shots. Manufacturers have been criticized for their slow production pace and have delivered millions of doses fewer than originally estimated.

“It’s really important for every available dose to be used as quickly and efficiently as possible,” Anne Schuchat of the U.S. Centers for Disease Control and Prevention said today during the agency’s weekly conference call.

New York City Supply

New York City received 800,000 doses of vaccine for swine flu, or H1N1 influenza, as of the beginning of the month, department spokeswoman Jessica Scaperotti said. The biggest portion -- 39 percent -- was allocated to the schools, while 21 percent was set aside for health care providers, 19 percent for hospitals, and 6 percent for private adult providers, including large employers with on-site medical personnel and clinics.

“Every provider must sign an agreement that they will only give the vaccine to those in the high-risk groups” designated by federal public health officials, Farley said.

The department released a list of large employer allotments that showed Citigroup, with 1,200 doses, received more than Memorial Sloan-Kettering Cancer Center, which was shipped 200. Goldman Sachs also received 200 doses. Mount Sinai Medical Center received 1,700 and Saint Vincent Catholic Medical Centers got 1,900. Morgan Stanley gave the 1,000 doses it received to hospitals, said spokeswoman Carissa Ramirez.

http://www.bloomberg.com/apps/news?pid=20601087&sid=awCHvhZqPcTo&pos=9

[cfoofme]

GenVec Signs New Contract to Support HIV and Influenza Vaccine Development
7:53a ET November 5, 2009 (PR NewsWire)
GenVec, Inc. (Nasdaq: GNVC) announced today that SAIC-Frederick, Inc. has signed a contract with GenVec for the development of influenza and HIV vaccines in support of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This four-year contract has a total value of over $22 million if all options are exercised. Over the next year, GenVec will receive approximately $2.6 million.

Under the contract, the vaccines would be comprised of genetic material supplied by the VRC and adenoviral vectors supplied by GenVec.

"This new contract supports important efforts in HIV and influenza. Given the heightened concerns about influenza, this contract is timely and we look forward to applying our novel technology to this problem," stated Dr. Paul Fischer, GenVec's President and CEO. "In particular, we are looking forward to working on a universal flu vaccine, which has the potential to protect against seasonal and pandemic outbreaks."

Work under this contract will include generation of HIV vaccine candidates, generation of a universal flu vaccine candidate, process and assay development for manufacture of vaccine candidates for clinical testing, and continued support of the HIV vaccine candidates currently in clinical testing.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product TNFerade is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, influenza, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

About the VRC

The Dale and Betty Bumpers Vaccine Research Center (VRC) at the National Institutes of Health was established to facilitate research in vaccine development. The VRC is dedicated to improving global human health through the rigorous pursuit of effective vaccines for human diseases. Established by former President Bill Clinton as part of an initiative to develop an AIDS vaccine, the VRC is a unique venture within the NIH intramural research program. Initially spearheaded by the National Institute of Allergy and Infectious Diseases (NIAID), the National Cancer Institute, and the NIH Office of AIDS Research, the VRC is now part of the NIAID organization.

About SAIC-Frederick

SAIC-Frederick, Inc., a wholly owned subsidiary of Science Applications International Corporation (SAIC), a Fortune 500(R) company, is the operations and technical support contractor for the National Cancer Institute's research and development center in Frederick, Md. This is a national laboratory dedicated to rapidly translating basic research into new technologies for diagnosing, treating, and preventing cancer and AIDS. SAIC-Frederick maintains a full suite of advanced technologies in areas such as nanotechnology, genomics and imaging; operates the federal government's drug and vaccine manufacturing facilities (VRC's Vaccine Pilot Plant and Biopharmaceutical Development Program); operates the high-performance Advanced Biomedical Computing Center; and supports more than 300 clinical trials for patients in the United States and around the world.

This project is being wholly funded with Federal funds from the National Cancer Institute, National Institutes of Health under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.

Investor Contact: Media Contact:
GenVec, Inc. Tiberend Strategic Advisors, Inc.
Danielle M. DiPirro Andrew Mielach
[phone] [phone]
[e-mail] [e-mail]




SOURCE GenVec, Inc.



http://www.genvec.com

[cfoofme]

CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns Hopkins University School of Medicine
9:45a ET November 6, 2009 (PR NewsWire)
CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today that an Institutional Review Board of The Johns Hopkins University School of Medicine (Johns Hopkins) has given clearance for the Company's first clinical study to proceed. As a result, Johns Hopkins will host the study, which will be led by Principal Investigator Jonathan M. Zenilman, MD, Professor of Medicine, Johns Hopkins School of Medicine and Chief of Infectious Diseases Division, Johns Hopkins Bayview Medical Center. As previously announced, this initial study will involve taking blood from hospitalized, laboratory-confirmed H1N1 patients and activating their cells with the LEAPS H1N1 investigational therapy in order to assess the cells' response as the basis for the planned future treatment of this patient population under a next-stage clinical trial protocol.

In September, the Company announced that the FDA had indicated that the Company could commence this study. In order for FDA to fully consider a next-stage clinical trial to evaluate LEAPS-H1N1 treatment of hospitalized patients with laboratory-confirmed H1N1 Pandemic Flu under an Exploratory IND, FDA has asked CEL-SCI to submit a detailed follow-up regulatory filing with extensive additional data.

"We are pleased that such a prestigious medical center has given clearance to proceed with this first study of our LEAPS-H1N1 treatment," said Geert Kersten, CEL-SCI's Chief Executive Officer. "Given the nature and severity of the virus, we are working diligently with our CRO and Johns Hopkins, and actively preparing submissions to the FDA, to support the fastest and most effective way to conduct clinical trials going forward for this unique investigational treatment."

The initiation of CEL-SCI's rapidly-accelerated LEAPS-H1N1 clinical development program builds on CEL-SCI's pioneering work with its LEAPS technology in the context of H1N1. CEL-SCI's L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) technology allows the Company to direct an immune response against specific disease epitopes. In the case of CEL-SCI's investigational LEAPS-H1N1 treatment, this involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu. This is intended to enable stimulation of the specifically-needed immune responses, while avoiding the administration of regions of H1N1, and other viruses, which may exacerbate the problem of cytokine storm, which CEL-SCI scientists believe may be involved in the death of some H1N1 patients.

L.E.A.P.S. technology is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize, non-recombinantly, proprietary immunogens. The L.E.A.P.S. technology combines a small peptide that activates the immune system with a small peptide from a disease-related protein, such as the H1N1 hemagglutinin molecule, to make an investigational product that induces defined immune responses. Each L.E.A.P.S. construct is composed of a T cell binding ligand (TCBL) which previously has demonstrated the ability to induce and elicit protective immunity and antigen-specific antibody production in animal models. Thus, extensive animal studies conducted to date indicate that any disease for which an antigenic sequence has been identified, such as infectious, parasitic, malignant or autoimmune diseases and allergies, are potential therapeutic or preventive sites for the application of L.E.A.P.S. technology.

About CEL-SCI Corporation

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine(R) which is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing an immunotherapy to prevent and treat swine and other influenzas using its L.E.A.P.S. technology platform and expects to soon finish the validation of its state-of-the-art facility in Maryland which it expects to utilize to launch aseptic filling for stem cell produced therapies and other biological products. The Company has operations in Vienna, Virginia, and Baltimore, Maryland.

For more information, please visit www.cel-sci.com.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, lack of regulatory clearance to proceed with clinical trials, an inability to duplicate the clinical results demonstrated in clinical studies that have been completed or that are initiated in the future, timely development of any potential products that can be shown to be safe and effective, unwillingness of regulatory authorities to engage in further regulatory dialogue, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital, and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K/A for the year ended September 30, 2008. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE CEL-SCI Corporation



http://www.cel-sci.com
http://ih.advfn.com/p.php?pid=nmona&cb=1257528397&article=40248733&symbol=A%5ECVM

[webpence]

Ukraine Nurses, Patients Make Masks as Flu Spreads (Update1)

Nov. 4 (Bloomberg) -- Nurses and patients at the town hospital in Chernivstsi, Ukraine, came together in an unusual task today: making their own protective masks.

“We bought gauze, people sat down and stitched the masks for the doctors,” said Oleh Kaminskyi, a doctor who works at the hospital. “Now we’re washing and ironing them.”

Ukraine, battling an outbreak of respiratory disease that’s sickened 478,400 people and killed 81, is struggling with a lack of protective equipment, antiviral drugs and laboratory facilities to confirm whether the H1N1 pandemic virus is causing the disease. Many residents are staying at home and turning to natural remedies such as garlic to ward off the virus.

Ukrainian President Viktor Yushchenko said in an urgent address to the nation today that the country’s flu outbreak is “unique” because three flu strains are spreading at the same time. That increases the risk of mutations of the viruses into a new strain, he said, citing unnamed domestic and foreign experts. The World Health Organization sent a team of scientists and advisers to Ukraine this week to investigate the outbreak.

The country’s Council for National Security and Defense is taking over management of the epidemic now, Yushchenko said, adding that the government has failed to control the spread of illness from the western Ternopil region.

‘Scared’

“Everyone is scared,” said Hryhoriy Stasiv, chief medical doctor at a division of Lviv’s First Clinical Hospital, in a telephone interview. “We don’t have masks. We don’t have medicines. We see on TV that drugs are on the way, but it’s been a while and they’re still not here.”

Ukraine, an eastern European nation with 46 million people that borders the European Union, has asked the U.S., the EU, NATO and neighbors for anti-flu drugs. Poland and Slovakia sent protective masks and Roche Holding AG’s drug Tamiflu after Yushchenko said the country couldn’t fight an outbreak of pandemic influenza alone.

Tamiflu has arrived at the hospital in Lviv, near the Polish border, though the medicine can only be used for severe cases of people confirmed to have H1N1, or swine flu, said Natalya Pohmurska, a doctor who works there. Because the local laboratory is closed, samples have to be shipped to Kiev, and take three days to return with a result, Pohmurska said.

Garlic and Honey

“I tell my patients to eat garlic, honey, herbal tea, cabbage and take lots of vitamins,” she said. “We lack masks. We got six for the week. Although they’re supposed to be used once, we wash them and iron them to be able to re-use them.”

http://www.bloomberg.com/apps/news?pid=20601087&sid=aT_13nVYV4c8&pos=9

[webpence]

One Flu Over the Ukraine's Nest

November 3rd, 2009 6:32 AM
by Edgar J. Steele


What moves me today? It appears that the massive biological pandemic that I have forecast for many years, most recently specifying this Fall (that's right now, folks), has arrived in the break-away Soviet republic of Ukraine over the past week. You say you haven't heard about it yet? You will. There has been no news coverage in the West so far, so near as I can tell, but this story is too big and moving too fast to cover up much longer. I have seen a number of Internet postings on the Ukrainian epidemic and, even, a few UTube videos already. I have heard the story developing since last week from correspondents of mine in Ukraine who have been witnessing things first hand. School and public offices have all been closed. President Yuschenko has declared a state of emergency and issued a plea for international help. Reports of up to 3,000 deaths (unconfirmed) already are leaking out.

So far, the worst of this outbreak is in Western Ukraine, in and around the city of Lviv, but a few hundred kilometers to the East, in the capital city of Kiev, nearly half the people now stalk the streets wearing surgical masks. It would be an understatement to say that the people of Ukraine are moving into full panic mode. I can see why. So should you. I will explain why in a moment.

Ukrainian authorities are unclear that this outbreak is the same as or, even, a close variant of the Swine Flu now sweeping over the planet. Maybe it is just a lethal mutation. Likely not, however. They are calling it both a viral pneumonia and bacteriological hemorrhagic fever. The symptoms mimic those of Swine Flu, though on steroids. People die with their lungs dissolving almost overnight, filled with fluids and blood. This is the exact, same pattern as followed by the 1917 Spanish Flu, which struck down the healthiest among the population, those with the strongest immune systems. The rampup over the summer has been identical to 1917, too.

Here's why you are at special risk if you are young and healthy: Your vital and responsive immune system is the very thing that kills you, by overreacting to the infection via what is called a Cytokeine Storm. I wrote about this process earlier this year, in Flu Happens. A great many of the people now dying have underlying conditions as well, particularly those of a respiratory nature such as asthma, when they take ill.

Now for the particularly interesting and sinister conspiracy twist (you just knew this was coming, didn't you?):

Incidentally, I have forecast in my Internet columns and my book, Defensive Racism, this very scenario, though I have not known where it would begin.

Three months ago, Israeli Mossad agent Joseph Moshe, who specializes in biological warfare, was taken down by Los Angeles police, allegedly for "threatening the White House." What wasn't reported by the media at the time was that Moshe just had "called into a radio show to warn people about a biological weapon that was being made by Baxter international that would be spread through vaccine and would cause a plague upon its release." http://www.huffingtonpost.com/2009/08/14/man-suspected-of-making-t_n_259330.html Moshe also claimed that Ukraine would be the country in which it first would be released. This was in early August. How did he know?

Three months ago, Moshe stated that this pandemic would begin in Ukraine, a country free of the flu until last week. That is too much for coincidence. Maybe it simply is coincidence, but I do not believe in coincidence. And, suddenly, lots of people are dying in Ukraine from this flu outbreak - a much more deadly form of the flu than has been seen anywhere else.

Baxter Pharmaceuticals has a vaccine development and production lab in Ukraine and in the past has been proven to have shipped dangerous live agents to other countries, notably AIDS in blood products that killed thousands of people a few years ago. This past spring, Czechoslovakia happened to test some Baxter vaccine and found live virus, something about which you may have heard.

Baxter, the source of the flu vaccine now being distributed over there, cannot be trusted! The Ukrainian people are not being told any of this or about what this Moshe character said just prior to being arrested in August over here. I am forwarding this column to all my friends in Ukraine tonight.

There is extreme danger from this flu pandemic in Ukraine right now and you should take especial precautions, wherever you live. Particularly, get a supply of Tamiflu, if possible, and start taking it at the first sign of symptoms (headache, fever, dry cough, aches/pains and extreme fatigue). It works. I have used it myself in the past. This flu operates very fast, often within just 3 - 6 hours, and is very deadly. You will not have time to get Tamiflu once you have symptoms.

I predict that we will see this all over the globe by the end of the month. This could kill a lot of people. A lot, as in millions. Already, you can bank upon this infection being in many other countries, now going through its gestation period. It is infectious before symptoms really manifest. We will know by this time next week.

Hang on, folks. I think this is just the crest. Now comes the plunge downward. Keep your hands and feet inside the ride at all times.


http://www.thepeoplesvoice.org/TPV3/Voices.php/2009/11/03/one-flu-over-the-ukraine-s-nest

[3percent]

RAD, buy?

[Rawnoc]

New Help for Doctors in Combating H1N1 (Swine Flu)

Nov 3, 2009 09:05:00 (ET)

CHESTER, N.Y., Nov 03, 2009 /PRNewswire-FirstCall via COMTEX/ -- As the outbreak of H1N1 (Swine Flu) intensifies, there is a growing need for greater speed and accuracy in collecting specimens from patients for testing to determine with what they've been infected. The government's Centers for Disease Control and Prevention (CDC) has issued interim guidance covering the collection, processing and testing of patient samples. Many state and local medical authorities have incorporated the CDC's recommendations into their own guidance.

That's why Repro-Med Systems, Inc., (REPR, Trade ), dba RMS Medical Products of Chester, NY, now offers a Specimen Collection Kit (SCK) for its RES-Q-VAC(R) portable hand held suction pump. The new kit makes it especially convenient for medical personnel to collect samples in accordance with guidance recommendations and their own local procedures. Samples can come from the nasal passages or throat of a patient suspected to have H1N1, RSV (Respiratory Syncytial Virus) or any other similar illness.

"Obtaining a reliable sample by inserting a swab deep into nasal passages can be tricky, especially when the patients are children who quickly become uncomfortable," noted Andrew Sealfon, President of RMS Medical Products, Inc. "This outbreak of swine flu seems to be hitting younger age groups especially hard," he added. Sealfon explained, "Using our new Specimen Collection Kit does away with the deep penetration and potential damage of using swab which can also contaminate the specimen. A few drops of saline solution are placed into the nostrils, then RES-Q-VAC suctions out the needed sample so quickly the patient doesn't have time to become discomforted."

The SCK consists of a sterile 55ml vial, a sterile 14-inch catheter, and a cap and label to help ensure proper transport of the sample. The RES-Q-VAC commonly is used for emergency suctioning of patients requiring airway management, such as when a patient becomes unconscious after a heart attack or stroke. It is used in hospitals, by ambulance personnel, fire/rescue personnel, and wherever reliable suctioning is needed. Because RES-Q-VAC works without electrical power or batteries, many institutions keep it in reserve for use during power outages and natural disasters.

Facilities already using RES-Q-VAC will only need to order a supply of the specimen collection kits to fit the suction pumps they already have.

Medical professionals can find out more about the RES-Q-VAC Specimen Collection Kit by contacting RMS Medical Products at 800-624-9600 or at [e-mail].

RMS Medical Products, manufacturer of the RES-Q-VAC designs and manufactures innovative medical devices directing its resources to the global markets for emergency medical products leading with its Res-Q-Vac Airway Suction System and infusion therapy with its Freedom60(R) Syringe Infusion Systems for use with antibiotics, subcutaneous immune globulin, pain control and chemotherapeutic drugs, among others. These cutting edge products improve the quality of health care while maintaining favorable operational costs. For further information, visit our web site at http://www.RMSmedicalproducts.com

[webpence]

UK Times Online flier on H1N1

http://extras.timesonline.co.uk/pdfs/swineflugraphic.pdf

Notice that they exclude mention of Vitamin D3 under the Treatment options" heading.

[Y worry Murray]

Swine Flu Cases: CBS reports CDC deception on swine flu cases

http://www.examiner.com/x-6495-US-Intelligence-Examiner~y2009m10d28-Swine-Flu-Cases-CBS-reports-CDC-deception-on-swine-flu-cases

[Y worry Murray]

WHO Memos 1972 Explains How to Turn Vaccines into a Means of Killing

Filed Under Big Government, Big Pharma, Pandemic

biohazardTwo key memorandums from WHO, discovered by Patrick Jordan, prove WHO has intentionally created the three-shot killer vaccine that people in the USA and other countries could soon be forced to take.

1972 WHO Bulletin 47, No 2 Memordanda #1 and #2 Virus-associated immunopathology:

Animal models and implications for human disease * technically outline the ability to create biological weapons in the form of vaccines that:

1) First totally disable the Immune System.

2) Load every cell of the Victim’s body up with Infection.

3) Switch the Immune System on causing the host to kill themselves in a Cytokine Storm.

One, Two, Three, Dead.

These WHO Memorandas describe the three-stage impact of the three “shots” many people will be forced to take this fall to allegedly treat a virus that WHO also helped create and release.

This is a crucial piece of evidence of WHO’s long-term genocidal intentions that could stand in any court of law because these memorandums give the best and fullest explanation WHO’s and affiliated labs (such as the CDC) current activities, such as their patenting of the most lethal bird flu viruses, their sending that virus to Baxter’s subsidiary in Austria, which weaponised it and sent out 72 kilos to 16 labs in four countries almost triggering a global pandemic.

For every crime, there needs to be motive, an indication that it was deliberate, planned. The WHO memorandums provide the evidence of just that deliberate, long-term planning to kill people by weakening their immune system by use of the first vaccine, injecting a live virus into their body by a second, and creating a cytokine storm using squalene in a third.

Download the WHO Memoranda on:

http://www.pubmedcentral.nih.gov/tocrender.fcgi?iid=169484

Scroll down until you find:

Memoranda

Virus-associated immunopathology : animal models and implications for human disease:

1. Effects of viruses on the immune system, immune-complex diseases, and antibody-mediated immunologic injury

Bull World Health Organ. 1972; 47(2): 257?264.
PMCID: PMC2480894

http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2480894&blobtype=pdf

Virus-associated immunopathology: animal models and implications for human disease:

2. Cell-mediated immunity, autoimmune diseases, genetics, and implications for clinical research

Bull World Health Organ. 1972; 47(2): 265?274
PMCID: PMC2480896

http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2480896&blobtype=pdf

[webpence]

Ohio Boy Given H1N1 Vaccine Against Mom's Wishes

OREGON, Ohio — A furious Ohio mother says her 7-year-old son, who has had problems with medications, was vaccinated for swine flu at school against her wishes.

Kim Lutheran works as a nurse and says her son, Matthew, has had bad reactions to medicine. So, she says she signed for "no consent" on a vaccination form and then circled her intentions with a black marker to make things clear to the boy's public school in the Toledo suburb of Oregon.

Lutheran says she learned Matthew still received a shot on Monday. She says the local health department must be held accountable.

Deputy Health Commissioner Larry Vasko says his agency has responded by changing the consent forms, telling parents not to sign or return them if they do not want their children vaccinated.

Lutheran told the Toledo Blade that her son was sent back to his classroom after handing in his no consent form, only to sent back to the nurse's office a short time later where he was given the H1N1 Vaccine.

"He got sent back again by himself into strange room with these strange people," she told the newspaper. "Supposedly three people looked at this piece of paper before he went to the R.N. who gave him the immunization. ... He's 7. He didn't know."

http://www.foxnews.com/story/0,2933,570214,00.html

[webpence]

Canada's Swine Flu Vaccine Ethically Produced, Though Safety Concerns Still an Issue

OTTAWA, October 27, 2009 (LifeSiteNews.com) - The swine flu vaccine approved for use in Canada by the country's federal drug regulator does not use aborted fetal cell lines in its manufacture.

The vaccine is produced by GlaxoSmithKline under the trade name Arepanrix, and is made with chick embryos.

Health Canada's Arepanrix product information leaflet says the "H1N1 antigen is prepared from virus grown in the allantoic cavity of embryonated hen's eggs."

This is welcome news for those considering the swine flu shot. The information is corroborated by evidence gathered by Children of God for Life, a pro-life group specializing in vaccine information, that shows that none of the US H1N1 vaccines are produced using aborted fetal cell lines.

"We are pleased that the pharmaceutical companies have chosen these (ethical) cell lines for this year's H1N1 vaccines," stated Executive Director Debi Vinnedge in a press release. "There are enough concerns about public health and safety without compounding the problems with moral issues."

She noted that there are two methods of possibly producing flu and H1N1 vaccines: chick embryo or cell culture. Chick embryo is the standard method that has been used to produce all flu vaccines for several years. The problem with this method is that every time a new batch of vaccines is needed, fresh eggs must be used, making it more difficult to get vaccines to the market in a timely manner for the flu season each year.

Because of this, the pharmaceutical industry has been working on a method that would speed development and processing time by using an established cell culture.

Unlike chick embryo, cell lines are developed, FDA approved and then frozen for future use so production time is considerably shorter. Several pharmaceutical companies such as Medimmune, Protein Science and Novavax are developing these future flu vaccines using a morally neutral cell culture, such as MDCK or insect cells.

But some manufacturers like Sanofi Pasteur and Vaxin are developing their cell culture vaccines using the aborted fetal cell line, PER C6.

Continue at...
http://www.lifesitenews.com/ldn/2009/oct/09102706.html

[webpence]

FLU VACCINES AND THE RISK OF CANCER

"A third type of cell line, called PER.C6 cells, is derived from retinal cells of aborted fetal tissues. The fetal cells are transformed by infecting them with an adenovirus, turning them into “immortalized” cells and the capability to replicate endlessly. By their very nature, these cells are neoplastic (cancer-causing); researchers refer to them as “oncogenic” cells. If tumors are formed when the cells are injected into experimental animals, the cell lines are beyond oncogenic; they are tumorigenic.

A serious concern about whole, live PER.C6 cells is that they are capable of causing tumors when transplanted into the skin of mice. The FDA requires a filtration method to be used during vaccine production that is designed to removes all cells before the final product is packaged. Even though several studies have been conducted to assure vaccine developers that PER.C6 cells do not cause cancer and do not contain stray tumor causing viruses,[4] the risk of the cells making their way into the final vaccine products remain.

The risks of residual retinal DNA and stray viral contaminants from the animal tissues getting into flu shots are real. DNA snips are classified as either “infectious” or “oncogenic” by researchers who worry that the stray DNA is being incorporated into the recipient’s DNA, even thought FDA regulations insist on the “importance of minimizing the risk of oncogenesis in vaccine recipients.” Manufacturers have been instructed to ensure the final vaccine contains less than 1 million residual animal cells and the amount of stray DNA is less than 10 ng. per vaccine.[5] These regulations admit that animal DNA is injected into human babies and adults with every shot."

http://www.newswithviews.com/Tenpenny/sherri123.htm